Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab (Simponi) vs placebo in active axial spondyloarthritis
2011-000311-34Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in axial spondyloarthritis (axSpA) and ankylosing spondylitis (AS) comparing Golimumab 50 mg with Placebo (2 arms). Primary endpoint: ASAS20 response at Week 16. Started Oct 2011; status: completed.
02
Drugs
golimumab
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2011-000311-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000311-34.